Cath Lab

The cardiac catheterization laboratory is used for diagnostic angiograms and percutaneous coronary interventions (PCI). Cath labs have also seen expanding use in recent years for transcatheter structural heart procedures. Some hospitals also share these labs with other subspecialties for catheter-based procedures in electrophysiology (EP), interventional radiology, peripheral artery disease (PAD), carotid and neuro interventional procedures and vascular surgery.

RSS icon
A transcatheter aortic valve replacement (TAVR) procedure being performed at Intermountain Healthcare. Image from Intermountain Healthcare

Predictors of 1-year mortality after TAVR are significantly different among men and women

Atrial fibrillation and peripheral artery disease, for example, are both predictors of mortality among women, but not men. 

Deepak Bhatt, MD, discusses the long-term, positive SYMPLICITY HTN-3 trial results presented at TCT 2022, and the future of renal denervation therapy to treat hypertension. #TCT

VIDEO: SYMPLICITY HTN-3 and the future of renal denervation

Deepak Bhatt, MD, MPH, details long-term outcomes from the SYMPLICITY HTN-3 trial, which show a lasting impact on patients with uncontrolled hypertension. 

Thumbnail

Late-breaking study examines IVL’s safety and effectiveness among real-life PAD patients

The new study, based on data from nearly 1,400 PAD patients who were treated with Shockwave Medical's IVL technology, was presented at VIVA22 in Las Vegas. 

Abiomed’s Impella RP Flex with SmartAssist heart pump has received approval from the U.S. Food and Drug Administration (FDA) for the treatment of acute right heart failure for up to 14 days.

Abiomed heart pump gains FDA approval to treat acute right heart failure

The device includes dual-sensor technology, an 11 French indwelling catheter and a flexible cannula.

A study that analyzed patient outcomes in coronary artery bypass grafting (CABG) in veterans showed outcomes for on-pump and off-pump procedures over 10 years to be similar. Photo by Jim Lennon

Repeat surgery vs. PCI in patients with a history of CABG: A complex decision for heart teams to consider

The study's authors examined data from nearly 10,000 patients for a new meta-analysis, presenting their findings in JTCVS Open.

A team of cardiologists and cardiac surgeons in Hong Kong has performed the first successful undermining iatrogenic coronary obstruction with radiofrequency needle procedure—or UNICORN for short—on a high-risk valve-in-valve transcatheter aortic valve replacement (TAVR) patient. The group wrote about their experience in Circulation: Cardiovascular Interventions, a journal launched and distributed by the American Heart Association.

Cardiologists make history, perform first UNICORN procedure during valve-in-valve TAVR

BASILICA was considered for the 67-year-old female patient, but UNICORN was seen as an overall better option. The full case study was published in Circulation: Cardiovascular Interventions.

Cordis acquires MedAlliance, known for its drug-eluting balloon technology, in deal that could surpass $1B

Cordis to acquire MedAlliance, known for its drug-eluting balloons, in deal that could surpass $1B

The acquisition includes an initial investment of $35 million and an upfront closing payment of $200 million. By 2029, if the companies reach all targeted regulatory and commercial milestones, the acquisition could cost Cordis up to $1.135 billion in all.

TEER reduces mitral regurgitation, boosts survival among cardiogenic shock patients

Researchers tracked outcomes data and imaging results from nearly 4,000 TEER patients, sharing their findings in the Journal of the American College of Cardiology.

Displaying 209 - 216 of 439
Design by Adaptive Theme